ERIS

Eris Lifesciences Share Price

₹1,464.60 -17.8 (-1.2%)

19 May, 2025 00:18

SIP TrendupStart SIP in ERIS

Start SIP

Performance

  • Low
  • ₹1,454
  • High
  • ₹1,491
  • 52 Week Low
  • ₹816
  • 52 Week High
  • ₹1,594
  • Open Price₹1,488
  • Previous Close₹1,482
  • Volume57,235

Investment Returns

  • Over 1 Month + 5.9%
  • Over 3 Month + 16.99%
  • Over 6 Month + 8.27%
  • Over 1 Year + 65.21%
SIP Lightning

Smart Investing Starts Here Start SIP with Eris Lifesciences for Steady Growth!

Invest Now

Eris Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 60.6
  • PEG Ratio
  • -4.1
  • Market Cap Cr
  • 19,946
  • P/B Ratio
  • 7.2
  • Average True Range
  • 68.14
  • EPS
  • 24.18
  • Dividend Yield
  • 0.5
  • MACD Signal
  • 29.14
  • RSI
  • 54.72
  • MFI
  • 66.23

Eris Lifesciences Financials

Eris Lifesciences Technicals

EMA & SMA

Current Price
₹1,464.60
-17.8 (-1.2%)
pointer
  • stock-down_img
  • Bearish Moving Average 1
  • stock-up_img
  • Bullish Moving Average 15
  • 20 Day
  • ₹1,445.46
  • 50 Day
  • ₹1,397.13
  • 100 Day
  • ₹1,358.10
  • 200 Day
  • ₹1,288.94

Resistance and Support

1469.9 Pivot Speed
  • R3 1,522.60
  • R2 1,506.80
  • R1 1,485.70
  • S1 1,448.80
  • S2 1,433.00
  • S3 1,411.90

What's your outlook on Eris Lifesciences?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Eris Lifesciences Ltd. is a leading Indian pharmaceutical company specializing in chronic and sub-chronic therapies. With 70% in-house manufacturing and a pan-India distribution network, Eris generates 86% of its revenue from chronic care, serving over 500,000 chemists nationwide.

Eris Lifesciences has an operating revenue of Rs. 2,737.05 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 21% is great, ROE of 15% is good. The company has a reasonable debt to equity of 25%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 11% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 6% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 40 which is a POOR score indicating inconsistency in earnings, a RS Rating of 88 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 108 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Eris Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-19 Audited Results
2025-02-07 Interim Dividend
2025-02-04 Quarterly Results
2024-10-25 Quarterly Results
2024-08-02 Quarterly Results
Date Purpose Remarks
2025-02-13 INTERIM Rs.7.35 per share(735%)Interim Dividend
2022-08-16 INTERIM Rs.7.35 per share(735%)Interim Dividend
2021-08-06 INTERIM Rs.6.01 per share(601%)Interim Dividend
View More

Eris Lifesciences F&O

Eris Lifesciences Shareholding Pattern

54.85%
16.59%
0.69%
8.43%
0%
9.16%
10.28%

About Eris Lifesciences

  • NSE Symbol
  • ERIS
  • BSE Symbol
  • 540596
  • Chairperson & Managing Director
  • Mr. Amit Bakshi
  • ISIN
  • INE406M01024

Similar Stocks to Eris Lifesciences

Eris Lifesciences FAQs

Eris Lifesciences share price is ₹1,464 As on 19 May, 2025 | 00:04

The Market Cap of Eris Lifesciences is ₹19945.7 Cr As on 19 May, 2025 | 00:04

The P/E ratio of Eris Lifesciences is 60.6 As on 19 May, 2025 | 00:04

The PB ratio of Eris Lifesciences is 7.2 As on 19 May, 2025 | 00:04

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23